Biotechnology Global News & Press Release Distribution

PharmAbcine Strengthens Scientific Advisory Board with a World-Renowned Expert in Ophthalmology

DAEJEON, South Korea, April 26, 2022 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced today the appointment ofQuan Dong Nguyen, MD, MSc, FAAO, FARVO, FASRS to its Scientific Adviso...

2022-04-26 20:00 1457

ITRI Named a Double Winner at Edison Awards 2022

HSINCHU, April 25, 2022 /PRNewswire/ -- The Edison Awards , one of the world's most revered innovation awards, announced the 2022 winners onApril 21 in Fort Myers, FL. At this year's program,ITRI won two awards in the sci...

2022-04-25 18:15 1754

ITRI Named a Double Winner at Edison Awards 2022

WuXi AppTec Reports Record First-Quarter In 2022

Revenue Up 71.2% Year-Over-Year to RMB8,474 Million Net Profit Attributable to Owners of the Company Up 9.5% Year-Over-Year to RMB1,643 Million Diluted Earnings Per Share (EPS) Up 3.9% Year-Over-Year to RMB0.53 Adjusted Non-IFRS[1] Net Profit Attributable to Owners of the Company Up 85.8% Ye...

2022-04-25 17:52 2749

World Malaria Day: Fosun Pharma's Self-Developed Artemisinin Series Become Symbol of China's Innovative Medicines

Together We Build a Malaria-Free World SHANGHAI, April 25, 2022 /PRNewswire/ -- World Malaria Day on April 25, is an occasion that aims to promote global malaria prevention and control. This year, World Malaria Day is marked under the theme "Harness innovation to reduce the malaria disease burde...

2022-04-25 17:00 2019

World Malaria Day: Fosun Pharma's Self-Developed Artemisinin Series Become Symbol of China's Innovative Medicines

Huison Virgin DHA Helps Infant Formula Safety Regulation and Innovation Development

* Application Solutions for Virgin DHA in Infant Formula Milk Powder Under the New National Standard XIAMEN, China, April 25, 2022 /PRNewswire/ -- On April 16-17, "Seminar on Infant Formula Perfection, Registration Guidance and Nutritional Ingredients Analysis under the New National Standard" w...

2022-04-25 16:09 1742

Huison Virgin DHA Helps Infant Formula Safety Regulation and Innovation Development

Porton Advanced and Sinorda Biomedicine Enter Strategic Collaboration to Accelerate Cell Therapy Development for Solid Tumors

SUZHOU, China, April 24, 2022 /PRNewswire/ -- Suzhou Porton Advanced Solutions Ltd. ('Porton Advanced') and Guizhou Sinorda Biomedicine Co. Ltd ('Sinorda Biomedicine') today announced a long-term strategic partnership in cell and gene therapy R&D and platform development.

2022-04-25 11:59 1726

Porton Advanced and Sinorda Biomedicine Enter Strategic Collaboration to Accelerate Cell Therapy Development for Solid Tumors

Bon Natural Life Limited Adds New Multi-Functional Health Supplements to Product Line

XI'AN, China, April 21, 2022 /PRNewswire/ -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or the "Company"), one of the leading bio-ingredient solutions providers in the natural, health and personal care industries, today announced that it has successfully developed new nutraceutical compounds –...

2022-04-21 21:00 3555

SoftBank Robotics Group Makes Strategic Equity Investment in Avalon SteriTech

Strive to Empower Public Health with Disinfection Robotics Solution in Post-Pandemic Era HONG KONG, April 20, 2022 /PRNewswire/ -- SoftBank Robotics Group Corp. ("SBRG") today announced its strategic equity investment in Avalon SteriTech ("Avalon"), marks a great step forward in strengthening th...

2022-04-20 15:07 1518

Samsung Biologics completes full acquisition of Samsung Bioepis

* Samsung Biologics has now fully acquired Samsung Bioepis, as a wholly owned subsidiary * First payment completed funded through paid-in capital * Accelerated growth expected in biosimilars and future novel therapeutics R&D INCHEON,South Korea, April 20, 2022 /PRNewswire/ -- Samsung Biologi...

2022-04-20 14:45 1923

FDA granted CMG901 Fast Track Designation for unresectable or metastatic gastric and gastroesophageal junction cancer which have relapsed and/or are refractory to approved therapies

CHENGDU, China, April 19, 2022 /PRNewswire/ -- Keymed Biosciences (2162.HK) announced that the U.S. Food and Drug Administration (FDA) granted CMG901 Fast Track Designation as monotherapy for the treatment of unresectable or metastatic gastric and gastroesophageal junction cancer which have relap...

2022-04-20 10:27 1503

ImmVira enters clinical development in combination therapy of MVR-T3011 IT and MEK inhibitor in the U.S.

SHENZHEN, China, April 19, 2022 /PRNewswire/ -- ImmVira announced that, company has reached a cooperation agreement with Roche to establish clinical research partnership recently, to conduct clinicalstudies in the U.S. on the combination therapy of ImmVira's MVR-T3011 IT and Roche's MEK inhibitor...

2022-04-20 08:00 1687

ImmVira enters clinical development in combination therapy of MVR-T3011 IT and MEK inhibitor in the U.S.

Bridge Biotherapeutics Enters into an Exclusive License Agreement with Shaperon to Strengthen Its IPF Franchise

* The licensing deal includes an upfront payment of USD 1.63 million, and may reach up toUSD 24.4 million in milestone payments and royalties * By strengthening the company's fibrotic disease development pipeline, Bridge will enhance its strategic focus on the development of comprehensive tre...

2022-04-19 09:19 1801

GeneQuantum and AIMEDBIO Collaborate on a First-in-Class Antibody -Drug-Conjugate

SUZHOU, China, April 18, 2022 /PRNewswire/ -- GeneQuantum Healthcare (Suzhou) Co., Ltd., a company specializing in site-specific bioconjugation for next generation biotherapeutics, has signed an agreement with a Korean biotech company, Aimed Bio Inc., to co-develop a First-in-Class therapeutic an...

2022-04-19 09:00 1558

A Brainwave Technology from Hyundai Mobis Proven to Reduce Drowsiness and Inattentive Driving by Up to 1/3

* M.Brain, the world's first brainwave technology developed last year, proven to be effective in a pilot application. * Cuts down drowsiness after meals by 30% and on highways by 20% max. Also, reduces time taken to recover attention by three times. * Hyundai Mobis secures competitiveness...

2022-04-18 21:00 2091

WuXi Biologics Receives Bioprocessing Excellence Award from IMAPAC

SINGAPORE, April 14, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global Contract Research, Development and Manufacturing Organization (CRDMO) service company, today announced that the company received the award for Bioprocessing Excellence in Viral Clearance and Safety at the A...

2022-04-15 09:03 2131

Asieris Pharmaceuticals Announces 2021 Annual Report: Steady Progress in Core Product Pipeline and Progressive Implementation of the Integrated Diagnosis and Treatment Commercialization Strategy

SHANGHAI, April 14, 2022 /PRNewswire/ -- Asieris Pharmaceuticals (688176.SH), a global innovative pharmaceutical company specializing in the treatment of genitourinary cancers and related major diseases, announced its 2021 annual report today. The company is currently making steady progress in mu...

2022-04-14 22:49 2282

Gracell Biotechnologies' Abstract on GC012F, a BCMA/CD19 Dual-targeting CAR-T Cell Therapy, Accepted for Presentation at 2022 ASCO Annual Meeting

PALO ALTO, Calif. and SUZHOU, China, April 14, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, toda...

2022-04-14 20:30 2308

Akeso Publishes Preclinical Results of PD-1/LAG-3 Bi-specific Antibody（AK129）at the American Association for Cancer Research (AACR) 2022 Annual Meeting

HONG KONG, April 14, 2022 /PRNewswire/ -- Akeso, Inc. (9926.HK) ( "Akeso" ), a China-based biopharmaceutical company focusing on the development and commercialization of innovative therapeutic antibodies for Oncology & Immunology, announced the publication of preclinical results of its PD-1/LAG-3...

2022-04-14 15:39 1897

Akeso Publishes Preclinical Results of PD-1/CD73 Bi-specific Antibody（AK131）at the American Association for Cancer Research (AACR) 2022 Annual Meeting

HONG KONG, April 14, 2022 /PRNewswire/ -- Akeso, Inc. (9926.HK) ( "Akeso" ), a China-based biopharmaceutical company focusing on the development and commercialization of innovative therapeutic antibodies for Oncology & Immunology, announced the publication of preclinical results of its PD-1/CD73 ...

2022-04-14 15:05 1668

Akeso Publishes Preclinical Results of TIGIT monoclonal antibody（AK127）at the American Association for Cancer Research (AACR) 2022 Annual Meeting

HONG KONG, April 14, 2022 /PRNewswire/ -- Akeso, Inc. (9926.HK) ( "Akeso" ), a China-based biopharmaceutical company focusing on the development and commercialization of innovative therapeutic antibodies for Oncology & Immunology, announced the publication of preclinical results of its anti-TIGIT...

2022-04-14 14:54 1900

Biotechnology